# Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

> **NCT01948180** · PHASE2 · TERMINATED · sponsor: **Cell Medica Ltd** · enrollment: 15 (actual)

## Conditions studied

- Lymphoma, Extranodal NK-T-Cell
- EBV

## Interventions

- **BIOLOGICAL:** baltaleucel-T

## Key facts

- **NCT ID:** NCT01948180
- **Lead sponsor:** Cell Medica Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2018-04-16
- **Final completion:** 2018-09-07
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Insufficient enrollment rate
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948180, "Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01948180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*